Search - tctmd.com

Displaying 221 - 240 of 342

Sort: Relevancy | Date

Real-world Data Show MitraClip Benefit in COAPT-Ineligible Patients

Michael O'Riordan

November 17, 2019

News Daily News

Sapien 3 Valve Approved in Europe for Low-Risk Patients

Michael O'Riordan

November 06, 2019

News Conference News TCT 2019

Predicting Final Valve Position After TAVR: Different Devices, Different Success

Michael O'Riordan

October 07, 2019

News Conference News TCT 2019

Leave It Be: PCI for Stable CAD Before or With TAVR Does Not Lower Mortality Risk

Michael O'Riordan

September 29, 2019

News Conference News TCT 2019

Oral Anticoagulation After TAVR Doesn’t Reduce Ischemic Cerebral Lesions: AUREA

Michael O'Riordan

September 28, 2019

News Conference News TCT 2019

Transcatheter Options Best for Tricuspid Regurgitation in Matched Registry Analysis

Michael O'Riordan

September 27, 2019

News Conference News TCT 2019

Leaflet Thickening and Impaired Motion No Worse With TAVR: PARTNER 3 CT

Michael O'Riordan

September 27, 2019

News Conference News TCT 2019

Personalized CT-Derived Modeling Guides Choices in Bicuspid Aortic Valve Disease

Michael O'Riordan

September 25, 2019

News Daily News

MIDAS Touch: Anatomic Strategy Dramatically Lowers Pacemaker Rate With Evolut Valves

Michael O'Riordan

August 29, 2019

News Daily News

FDA: Class I Recall for Burst Balloons With Sapien 3 Ultra Delivery System

Michael O'Riordan

August 22, 2019

News Daily News

No Volume-Outcome Link With Watchman for LAA Closure? Single-Center Study

Michael O'Riordan

August 19, 2019

News Daily News

FDA Expands TAVR Indication to Low-Risk Patients

Michael O'Riordan

August 16, 2019

News Daily News

Better Outcomes, Fewer Complications Among Higher-Volume MitraClip Sites

Michael O'Riordan

July 17, 2019

News Daily News

Elevated BP Linked to Risk of Valvular Heart Disease, Including Aortic Stenosis

Michael O'Riordan

July 12, 2019

News Daily News

Evolut Valves: Initial Positioning Can Be Optimized for Future Coronary Access

Michael O'Riordan

July 10, 2019

News Conference News TVT 2019

Better Hemodynamics, Less Mismatch With Self-Expanding TAVR vs Surgery

Michael O'Riordan

June 20, 2019

News Conference News TVT 2019

Surgical Risk Should Be ‘Off the Table’ When Deciding on Eligibility for TAVR

Michael O'Riordan

June 19, 2019

News Conference News TVT 2019

Faster and Larger Gains in Physical Function With TAVR Than With Surgery: SURTAVI

Michael O'Riordan

June 17, 2019

News Conference News TVT 2019

What’s The Future For Treating Mitral Valve Disease: Repair, Replace, or Combination Approaches?

Michael O'Riordan

June 14, 2019

News Conference News TVT 2019

PCI During or After TAVR No Riskier Than PCI Before Valve Replacement

Michael O'Riordan

June 13, 2019

Advertisement

Real-world Data Show MitraClip Benefit in COAPT-Ineligible Patients

Sapien 3 Valve Approved in Europe for Low-Risk Patients

Predicting Final Valve Position After TAVR: Different Devices, Different Success

Leave It Be: PCI for Stable CAD Before or With TAVR Does Not Lower Mortality Risk

Oral Anticoagulation After TAVR Doesn’t Reduce Ischemic Cerebral Lesions: AUREA

Transcatheter Options Best for Tricuspid Regurgitation in Matched Registry Analysis

Leaflet Thickening and Impaired Motion No Worse With TAVR: PARTNER 3 CT

Personalized CT-Derived Modeling Guides Choices in Bicuspid Aortic Valve Disease

MIDAS Touch: Anatomic Strategy Dramatically Lowers Pacemaker Rate With Evolut Valves

FDA: Class I Recall for Burst Balloons With Sapien 3 Ultra Delivery System

No Volume-Outcome Link With Watchman for LAA Closure? Single-Center Study

FDA Expands TAVR Indication to Low-Risk Patients

Better Outcomes, Fewer Complications Among Higher-Volume MitraClip Sites

Elevated BP Linked to Risk of Valvular Heart Disease, Including Aortic Stenosis

Evolut Valves: Initial Positioning Can Be Optimized for Future Coronary Access

Better Hemodynamics, Less Mismatch With Self-Expanding TAVR vs Surgery

Surgical Risk Should Be ‘Off the Table’ When Deciding on Eligibility for TAVR

Faster and Larger Gains in Physical Function With TAVR Than With Surgery: SURTAVI

What’s The Future For Treating Mitral Valve Disease: Repair, Replace, or Combination Approaches?

PCI During or After TAVR No Riskier Than PCI Before Valve Replacement

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content